B+
Bull case
20%
Probability
Target price
$8.00
+24.6% vs current
TSHA
Taysha Gene TherapiesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-18
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$5.50
-14.3% vs current
B-
Bear case
25%
Probability
Target price
$3.00
-53.3% vs current
AI sentiment snapshot
Latest data as of 2025-12-06
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+33.3
Score
AI commentary
Market tone is cautious/neutral: filings highlight limited cash runway and the need for financing, which weighs on sentiment, while the pipeline retains investor interest given CNS program potential [#10-Q-2025-09-30, #IR-pipeline-2025]. Recent discourse favors watchful waiting for clinical readouts or partnership signals before re‑rating [#IR-pipeline-2025].
RankAlpha Sentiment AI - 2025-12-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventClinical data readouts from CNS programsHigh impact
Upcoming readouts or cohort updates from Taysha's CNS gene therapy programs could materially re-rate the stock; timing and endpoints remain program-dependent (company pipeline summaries) [#IR-pipeline-2025].
-catalystPartnerships / asset-sale optionalityHigh impact
Strategic partnering or out‑licensing of assets (to extend runway or de‑risk development) is feasible and would be value-accretive if achieved; probability moderate based on sector dynamics [#10-Q-2025-09-30].
2026-06-30catalystCash runway into mid-2026 (10-Q)High impact
Company reported cash and cash equivalents of $104.8M as of 2025-09-30 and stated cash is expected to fund operations into mid-2026, creating near-term financing/dilution risk [#10-Q-2025-09-30].
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-06 • Updated nightlySource: Internal modelMethodology